Drugs / Investigational Trivalent Influenza Vaccine with alternate B strain
Investigational Trivalent Influenza Vaccine with alternate B strain
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01240746 | Nov 2010 → Dec 2011 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Investigational Trivalent Influenza Vaccine with alternate B strain | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01240746 ↗ |
| Modality | Vaccine | “Investigational Trivalent Influenza Vaccine with alternate B strain, No Preservative” NCT01240746 ↗ |
| Route | Intramuscular | “0.25 mL (6 to 35 months) or 0.5 mL (3 to \<9 years), Intramuscular” NCT01240746 ↗ |